



**bioMérieux launches BIOFIRE® FIREWORKS™  
a cutting-edge, data-driven software solution  
that takes BIOFIRE® Systems to the next level**

Marcy-l'Étoile, France – April 5, 2023

**bioMérieux, a world leader in the field of *in vitro* diagnostics, launches BIOFIRE® FIREWORKS™, an innovative and integrated software solution for BIOFIRE® Systems optimizing laboratory services and supporting data-driven decisions. This software is the newest addition to the BIOMÉRIEUX VISION SUITE – the company’s portfolio of Data and IT Solutions supporting increased efficiency and productivity in laboratories worldwide.**

Tracking test results, surveillance data, instrument performance and productivity, is not an easy task especially for laboratories with busy staff and ever-increasing workloads. Decentralized data management poses a further challenge as this approach lacks the comprehensive visibility that is vital for streamlining laboratory operations and workflow.

Robust, centralized data management is the key to unlocking the full capabilities of modern laboratories. By consolidating all BIOFIRE® FILMARRAY® systems, used by laboratories, into one centralized location, BIOFIRE® FIREWORKS™ enables real time connectivity of not only central labs but off-site laboratories as well. By offering complete oversight into fleet performance of BIOFIRE® Systems and enabling access to data from anywhere at any time, laboratories can optimize their workflows and further gain autonomy and command over their operations.

BIOFIRE® FIREWORKS™, with its user-friendly interface, customizable filters, and seamless integration, can be the centralized data management tool laboratories have been seeking.

Mark Miller, Executive Vice President, Chief Medical Officer, noted: *“With 70% of medical decisions relying on laboratory test results, this type of data has become the lifeblood of healthcare. Now, BIOFIRE® FIREWORKS™ allows labs to harness the power of data, unlocking insights that were previously hidden. With every sample analyzed and every result delivered, bioMérieux empowers labs to save lives and improve patient outcomes.”*

BIOFIRE® FIREWORKS™ was designed, developed, and implemented to keep patient and customer data safe, adhering to industry standards and regulations. Customers have complete control over their data, allowing them to manage their information as they see fit.

BIOFIRE® FIREWORKS™ is already in use at several pilot sites across the world. The initial launch is scheduled in April 2023 in selected countries (Austria, France, Germany, Hungary, Italy, Spain, South Korea, and United States of America) and will roll out to other countries progressively.

A next step in the development of the BIOFIRE® FIREWORKS™ will be the full integration of [BIOFIRE® Syndromic Trends](#) – a global disease surveillance network

PRESS RELEASE



created by bioMérieux for BIOFIRE® Panel users. The synergistic union of these two solutions will further strengthen BIOFIRE® FIREWORKS™ as a powerful and comprehensive tool for laboratories across the world.

## ABOUT BIOMÉRIEUX VISION SUITE

BIOMÉRIEUX VISION SUITE turns laboratory and hospital data into insightful and actionable information to support diagnostic and clinical decisions at all stages, from individual patient care to public health surveillance, to better support Antimicrobial Stewardship. By providing a comprehensive suite of software products and services that collect, analyze and merge various sources of data, BIOMÉRIEUX VISION SUITE empowers our users to make the right decisions at the right time. [Learn more](#)

## BIOMÉRIEUX GAME CHANGER FOR 60 YEARS

### *Pioneering Diagnostics*

A world leader in the field of *in vitro* diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2022, revenues reached €3.6 billion, with over 90% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in food, pharmaceutical and cosmetic products.

[www.biomerieux.com](http://www.biomerieux.com).



bioMérieux is listed on the Euronext Paris stock market.

Symbol: BIM – ISIN Code: FR0013280286

Reuters: BIOX.PA/Bloomberg: BIM.FP

## CONTACTS

### INVESTORS RELATIONS

Franck Admant

Tel.: +33 (0)4 78 87 20 00

[Investor.relations@biomerieux.com](mailto:Investor.relations@biomerieux.com)

### MEDIA RELATIONS

CORPORATE

bioMérieux

Romain Duchez

Tel.: +33 (0)4 78 87 21 99

[media@biomerieux.com](mailto:media@biomerieux.com)

UNITED STATES

bioMérieux

Stephen Norton

Tel. : +1 801-940-9051

[stephen.norton@biomerieux.com](mailto:stephen.norton@biomerieux.com)

FRANCE

Image Sept

Claire Doligez

Tel.: +33 (0)1 53 70 74 48

[cdoligez@image7.fr](mailto:cdoligez@image7.fr)

PRESS RELEASE